Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma
29 mai 2020 08h00 HE
|
Kura Oncology, Inc.
– Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC – – Outcomes with approved therapies are poor, with reported median OS of 5-8...
Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program
13 mai 2020 17h00 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
08 mai 2020 16h03 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020
07 mai 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock
06 mai 2020 09h00 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Announces Commencement of Public Offering of Common Stock
05 mai 2020 16h01 HE
|
Kura Oncology, Inc.
SAN DIEGO, May 05, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports First Quarter 2020 Financial Results
04 mai 2020 16h05 HE
|
Kura Oncology, Inc.
– Enhanced focus on tipifarnib in HRAS mutant HNSCC and KO-539 menin inhibitor in NPM1-mutant and KMT2A(MLL)-rearranged AML – – Three abstracts accepted for presentation at ASCO, including mature...
Kura Oncology to Report First Quarter 2020 Financial Results
29 avr. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, April 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas
03 mars 2020 07h30 HE
|
Kura Oncology, Inc.
– Second Fast Track designation for tipifarnib further highlights potential for tipifarnib to address unmet need for patients – – Company plans to initiate a registration-directed trial of tipifarnib...
Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results
25 févr. 2020 16h03 HE
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 – – Company preparing to initiate a...